Association between C-reactive protein and type 2 diabetes in a Tunisian population

Inflammation

Volumn 35, Issue 2, 2012, Pages 684-689

  Belfki, Hanen ^a   Ben Ali, Samir ^a   Bougatef, Souha ^a   Ben Ahmed, Decy ^c   Haddad, Najet ^c   Jmal, Awatef ^b   Abdennebi, Monia ^b   Ben Romdhane, Habiba ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b Mahmoud El Matri Hospital of Ariana   (Tunisia)

^c Center of Basic Health Care of Ariana Essoghra   (Tunisia)

Author keywords

C reactive protein; Inflammation; Insulin resistance; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TUNISIA;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; TUNISIA;

EID: 84863775272     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-011-9361-1     Document Type: Article

References (46)

1. Lyra, R., M. Oliveira, D. Lins, and N. Cavalcanti. 2006. Prevention of type 2 diabetes mellitus. Arq Bras Endocrinol Metab 50: 239-249. (Pubitemid 43799110)
2. Bogaert, Y.E., and R.W. Schrier. 2011. Into the future: prevention of diabetes. Contributions to Nephrology 170: 256-263.
3. Wong, T.Y., N. Cheung,W.T. Tay, J.J.Wang, T. Aung, S.M. Saw, S.C. Lim, E.S. Tai, and P. Mitchell. 2008. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 115: 1869-1875.
4. Howard, B.V., B.L. Rodriguez, P.H. Bennett, M.I. Harris, R. Hammam, L.H. Kuller, T.A. Pearson, and J. Wylie-Rosett. 2002. Prevention Conference VI: Diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 105: 132-137.
5. Nabipour, I., K. Vahdat, S.M. Jafari Seyed, S. Beigi, M. Assadi, F. Azizi, and Z. Sanjdideh. 2008. Elevated high sensitivity c-reactive protein is associated with type 2 diabetes mellitus: the Persian Gulf healthy heart study. Endocrine Journal 55: 717-722.
6. Pickup, J.C., M.B. Mattock, G.D. Chusney, and D. Burt. 1997. NIDDM as disease of the immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292. (Pubitemid 27469668)
7. Pickup, J.C., and M.A. Crook. 1998. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248. (Pubitemid 28449093)
8. Morohoshi, M., K. Fujisawa, I. Uchimura, and F. Numano. 1996. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 45: 954-959. (Pubitemid 26225513)
9. Guha, M., W. Bai, J.L. Nadler, and R. Natarajan. 2000. Molecular mechanisms of tumor necrosis factor α gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and - independent pathways. Journal of Biological Chemistry 275: 17728-17739. (Pubitemid 30430822)
10. Hirschfield, G., and M. Pepys. 2003. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96: 793.
11. Pearson, T.A., G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon 3rd, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith Jr., K. Taubert, R.P. Tracy, and F. Vinicor. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499-511. (Pubitemid 36158056)
12. Ridker, P.M., M. Cushman, M.J. Stampfer, R.P. Tracy, and C.H. Hennekens. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine 336: 973-979. (Pubitemid 27152782)
13. Yeh, E.T., and J.T. Willerson. 2003. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107: 370-371.
14. Ridker, P.M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369. (Pubitemid 36158034)
15. Liuzzo, G., L.M. Biasucci, J.R. Gallimore, R.L. Grillo, A.G. Rebuzzi, M.B. Pepys, and A. Maseri. 1994. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New Engl J Med 331: 417-424. (Pubitemid 24247397)
16. Ridker, P.M., C.H. Hennekens, J.E. Buring, and N. Rifai. 2000. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl J Med 342: 836-843. (Pubitemid 30165206)
17. Festa, A., R. D'Agostino Jr., G. Howard, L. Mykkänen, R.P. Tracy, and S.M. Haffner. 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47. (Pubitemid 30430551)
18. Pradhan, A.D., J.E. Manson, N. Rifai, J.E. Buring, and P.M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334. (Pubitemid 32656163)
19. Nakanishi, S., K. Yamane,N.Kamei,M. Okubo, and N. Kohno. 2003. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 26: 2754-2757. (Pubitemid 37205542)
20. Thorand, B., J. Baumert, H. Kolb, C. Meisinger, L. Chambless, W. Koenig, and C. Herder. 2007. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 30: 854-860. (Pubitemid 46556577)
21. Hu, G., P. Jousilahti, J. Tuomilehto, R. Antikainen, J. Sundvall, and V. Salomaa. 2009. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. Journal of Clinical Endocrinology and Metabolism 94: 2099-2105.
22. Krakoff, J., T. Funahashi, C.D. Stehouwer, C.G. Schalkwijk, S. Tanaka, Y. Matsuzawa, S. Kobes, P.A. Tataranni, R.L. Hanson, W.C. Knowler, and R.S. Lindsay. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26: 1745-1751. (Pubitemid 36929114)
23. Dehghan, A., I. Kardys, M.P. de Maat, A.G. Uitterlinden, E.J. Sijbrands, A.H. Bootsma, T. Stijnen, A. Hofman, M.T. Schram, and J.C. Witteman. 2007. Genetic variation, C-reactive protein levels, and incidence of diabetes. Diabetes 56: 872-878. (Pubitemid 46348467)
24. Lee, C.C., A.I. Adler, M.S. Sandhu, S.J. Sharp, N.G. Forouhi, S. Erqou, R. Luben, S. Bingham, K.T. Khaw, and N.J. Wareham. 2009. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52: 1040-1047.
25. Friedewald, W.T., R.T. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clinical Chemistry 18: 449-502.
26. Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
27. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997. Diabetes Care 20:1183-1197.
28. Dandona, P., A. Aljada, A. Chaudhuri, and A. Bandyopadhyay. 2003. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complication in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88: 2422-2429. (Pubitemid 36724406)
29. Doi, Y., Y. Kiyohara, M. Kubo, T. Ninomiya, Y. Wakugawa, K. Yonemoto, M. Iwase, and M. Iida. 2005. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 28: 2497-2500. (Pubitemid 41384300)
30. Freeman, D.J., J. Norrie, M.J. Caslake, A. Gaw, I. Ford, G.D. Lowe, D.S. O'Reilly, C.J. Packard, N. Sattar, and West of Scotland Coronary Prevention Study. 2002. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51: 1596-1600. (Pubitemid 34826630)
31. Huffman, F.G., S. Whisner, G.G. Zarini, and S. Nath. 2010. Waist circumference and BMI in relation to serum high sensitivity Creactive protein (hs-CRP) in Cuban Americans with and without type 2 diabetes. International Journal of Environmental Research and Public Health 7: 842-852.
32. Shemesh, T., K.G. Rowley, A. Jenkins, J. Brimblecombe, J.D. Best, and K. O'Dea. 2007. Differential association of C-reactive protein with adiposity in men and women in an Aboriginal community in northeast Arnhem Land of Australia. International Journal of Obesity 31: 103-108. (Pubitemid 46006022)
33. Baumann, H., and J. Gauldie. 1990. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Molecular Biology & Medicine 7: 147-159. (Pubitemid 20198145)
34. Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. The Journal of Clinical Investigation 95: 2409-2415.
35. Warren, R.S., H.F. Starnes Jr., J.L. Gabrilove, H.F. Oettgen, and M.F. Brennan. 1987. The acute metabolic effects of tumor necrosis factor administration in humans. Archives of Surgery 122: 1396-1400. (Pubitemid 18058287)
36. Vgontzas, A.N., D.A. Papanicolaou, E.O. Bixler, A. Kales, K. Tyson, and G.P. Chrousos. 1997. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. Journal of Clinical Endocrinology and Metabolism 82: 1313-1316. (Pubitemid 27200394)
37. Yamada, S., T. Gotoh, Y. Nakashima, K. Kayaba, S. Ishikawa, N. Nago, Y. Nakamura, Y. Itoh, and E. Kajii. 2001. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Jichi Med School Cohort Study. Am J Epidemiol 153: 1183-1190. (Pubitemid 32552276)
38. Saijo, Y., N. Kiyota, Y. Kawasaki, Y. Miyazaki, J. Kashimura, M. Fukuda, and R. Kishi. 2004. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes, Obesity & Metabolism 6: 249-258. (Pubitemid 38807798)
39. Pickup, J.C. 2004. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-823. (Pubitemid 38280558)
40. Grunfeld, C., and K.R. Feingold. 1996. Regulation of lipid metabolism by cytokines during host defense. Nutrition 12: S24-S26.
41. Nishikawa, T., D. Edelstein, X.L. Du, S. Yamaguchi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino, and M. Brownlee. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 404: 787-790. (Pubitemid 30212409)
42. Ceriello, A., and E. Motz. 2004. Is oxidative stress the pathogenic mechanismunderlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 816-823. (Pubitemid 38620857)
43. Cleland, S.J., N. Sattar, J.R. Petrie, N.G. Forouhi, H.L. Elliott, and J.M. Connell. 2000. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Science 98: 531-535. (Pubitemid 30261001)
44. Tooke, J. 1999. The association between insulin resistance and endotheliopathy. Diabetes, Obesity & Metabolism 1: S17-S22.
45. Stewart, M.W., D.T. Cirkel, K. Furuseth, J. Donaldson, N. Biswas, M.G. Starkie, C. Phenekos, and A. Hamann. 2006. Effect of metformin plus rosiglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabetic Medicine 23: 1069-1078. (Pubitemid 44401135)
46. Ridker, P.M., C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, and E. Raunwald. 2005. C-reactive protein levels and outcomes after statin therapy. N Eng J Med 352: 20-28. (Pubitemid 40075677)